<DOC>
	<DOCNO>NCT01548404</DOCNO>
	<brief_summary>To assess clinical efficacy repeat subcutaneous ( SC ) dose REGN668/SAR231893 adult patient moderate-to-severe atopic dermatitis ( AD ) .</brief_summary>
	<brief_title>Study REGN668/SAR231893 Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>The inclusion criterion include , limited , follow : 1 . Male female , 18 year old 2 . Chronic Atopic Dermatitis least 3 year 3 . History inadequate response stable ( &gt; /= 1 month ) regimen topical corticosteroid calcineurin inhibitor treatment AD within 3 month screen visit 1 . Prior treatment REGN668 2 . Presence certain laboratory abnormality screen visit 3 . Treatment investigational drug within 8 week 4 . Treatment live ( attenuate ) vaccine within 12 week baseline visit 5 . Certain treatment medical procedure , undertaken within particular timeframe prior baseline visit , preclude eligibility participation study : 6 . Known history human immunodeficiency virus ( HIV ) infection 7 . History malignancy within 5 year baseline visit , certain exception 8 . Planned surgical procedure length patient 's participation study 9 . History clinical parasite infection . 10 . Any medical psychiatric condition , opinion investigator sponsor 's medical monitor , would place patient risk , interfere participation study , interfere interpretation study result 11 . Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>